83_FR_47812 83 FR 47629 - Government-Owned Inventions; Availability for Licensing

83 FR 47629 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 183 (September 20, 2018)

Page Range47629-47630
FR Document2018-20484

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 83 Issue 183 (Thursday, September 20, 2018) 
[Federal Register Volume 83, Number 183 (Thursday, September 20, 2018)]
[Notices]
[Pages 47629-47630]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-20484]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Barry Buchbinder, Ph.D., 240-627-3678; 
[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: 
    Technology description follows.

Glycan-Masked Engineered Outer Domains of HIV-1 GP120 and Their Use

    Description of Technology:
    The VRC01-class of potent, broadly neutralizing antibodies (bnAbs) 
targets the conserved CD4-binding site (CD4bs) of HIV-1 Env which has 
been a major target of HIV-vaccine design. The current best priming 
immunogen to engage the VRC01-class germline precursors is the eOD-GT8 
60mer, which elicits VRC01-class precursors in multiple transgenic 
mouse models. However, a large proportion of the antibodies elicited by 
eOD-GT8 60mer are non-CD4bs or ``off-target'' antibodies, undermining 
its effectiveness in eliciting the VRC01-class bnAb precursors.
    Researchers at the Vaccine Research Center (VRC) of the National 
Institute of Allergy and Infectious Diseases introduced multiple N-
linked glycosylation sites to mask non-CD4bs regions of eOD-GT8 60mer 
to focus the antibody immune response to the CD4bs.
    Several glycan-masked mutants showed significantly decreased 
antibody binding to non-CD4bs ``off-target'' epitopes while maintaining 
strong binding to CD4bs-specific bnAbs. Furthermore, in vivo studies 
showed that immunization with the best glycan-masked eOD-GT8 mutants 
resulted in significant increases in the elicitation of CD4bs-specific 
serum antibodies, CD4bs-specific B cells in the spleen, and VRC01-class 
precursors, compared to immunization with the parental eOD-GT8 
immunogen. In conclusion, because of their improved antigenic and 
immunogenic profiles, glycan-masked eOD-GT8 60mer mutants may serve as 
improved priming immunogens to elicit VRC01-class bnAbs in humans.
    Potential Commercial Applications:
     HIV-1 vaccine--the priming component in a prime-boost 
approach.
    Competitive Advantages:
     Reduced off-target immunogenicity.
     Improved efficacy in eliciting precursors for broadly 
neutralizing CD4bs antibodies.
     Facilitates the development of VRC01-class bnAbs in 
humans.
    Development Stage: In vivo testing (rodents).
    Inventors: John R. Mascola (NIAID), Hongying Duan (NIAID), Xuejun 
Chen (NIAID), Cheng Cheng (NIAID) and Jeffrey C. Boyington (NIAID).
    Publications: Duan, H. et al., Glycan Masking Focuses Immune 
Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of 
VRC01-Class Precursor Antibodies. Immunity 49, 301 (2018).
    Intellectual Property: HHS Reference Number E-083-2017 includes 
U.S. Provisional Patent Application Number 62/476,397 filed 03/24/2017 
and PCT

[[Page 47630]]

Application Number PCT/US2018/024330 filed 03/26/2018.
    Licensing Contact: Barry Buchbinder, Ph.D., 240-627-3678; 
[email protected].

    Dated: September 10, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-20484 Filed 9-19-18; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 183 / Thursday, September 20, 2018 / Notices 47629 order to facilitate their entry into the government-issued photo ID, driver’s license, The VRC01-class of potent, broadly building. Contact Ann Ferrero using the or passport) and to state the purpose of their neutralizing antibodies (bnAbs) targets information mentioned above by visit. the conserved CD4-binding site (CD4bs) Information is also available on the Thursday, October 18, 2018, 12:00 p.m. Institute’s/Center’s home page: NCRA: http:// of HIV-1 Env which has been a major ET. All attendees are required to present deainfo.nci.nih.gov/advisory/ncra/ncra.htm, target of HIV-vaccine design. The government-issued identification prior where an agenda and any additional current best priming immunogen to to entry. The meeting will also be information for the meeting will be posted engage the VRC01-class germline accessible via webcast. Instructions on when available. precursors is the eOD-GT8 60mer, how to access the meeting via webcast (Catalogue of Federal Domestic Assistance which elicits VRC01-class precursors in will be provided upon registration. Program Nos. 93.392, Cancer Construction; multiple transgenic mouse models. 93.393, Cancer Cause and Prevention However, a large proportion of the Amy P. McNulty, Research; 93.394, Cancer Detection and antibodies elicited by eOD-GT8 60mer Acting Director, Division of the Executive Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology are non-CD4bs or ‘‘off-target’’ Secretariat. Research; 93.397, Cancer Centers Support; antibodies, undermining its [FR Doc. 2018–20428 Filed 9–19–18; 8:45 am] 93.398, Cancer Research Manpower; 93.399, effectiveness in eliciting the VRC01- BILLING CODE 4165–15–P Cancer Control, National Institutes of Health, class bnAb precursors. HHS) Researchers at the Vaccine Research Dated: September 14, 2018. Center (VRC) of the National Institute of DEPARTMENT OF HEALTH AND Allergy and Infectious Diseases HUMAN SERVICES Melanie J. Pantoja, introduced multiple N-linked Program Analyst, Office of Federal Advisory National Institutes of Health Committee Policy. glycosylation sites to mask non-CD4bs regions of eOD-GT8 60mer to focus the [FR Doc. 2018–20418 Filed 9–19–18; 8:45 am] National Cancer Institute; Notice of antibody immune response to the BILLING CODE 4140–01–P Meeting CD4bs. Several glycan-masked mutants Pursuant to section 10(d) of the showed significantly decreased Federal Advisory Committee Act, as DEPARTMENT OF HEALTH AND antibody binding to non-CD4bs ‘‘off- amended, notice is hereby given of a HUMAN SERVICES target’’ epitopes while maintaining meeting of the National Cancer Institute strong binding to CD4bs-specific bnAbs. Council of Research Advocates. National Institutes of Health Furthermore, in vivo studies showed The meeting will be open to the Government-Owned Inventions; that immunization with the best glycan- public, with attendance limited to space Availability for Licensing masked eOD-GT8 mutants resulted in available. Individuals who plan to significant increases in the elicitation of attend and need special assistance, such AGENCY: National Institutes of Health, CD4bs-specific serum antibodies, as sign language interpretation or other HHS. CD4bs-specific B cells in the spleen, and reasonable accommodations, should ACTION: Notice. VRC01-class precursors, compared to notify the Contact Person listed below immunization with the parental eOD- in advance of the meeting. The open SUMMARY: The invention listed below is owned by an agency of the U.S. GT8 immunogen. In conclusion, session will be videocast and can be because of their improved antigenic and accessed from the NIH Videocasting and Government and is available for licensing to achieve expeditious immunogenic profiles, glycan-masked Podcasting website (http:// eOD-GT8 60mer mutants may serve as videocast.nih.gov). commercialization of results of federally-funded research and improved priming immunogens to elicit Name of Committee: National Cancer development. Foreign patent VRC01-class bnAbs in humans. Institute Council of Research Advocates. Potential Commercial Applications: applications are filed on selected Date: October 19, 2018. • HIV-1 vaccine—the priming Time: 9:00 a.m. to 4:30 p.m. inventions to extend market coverage component in a prime-boost approach. Agenda: Welcome and Chairman’s for companies and may also be available Competitive Advantages: Remarks, NCI Updates, Legislative Update, for licensing. • Reduced off-target immunogenicity. Budget Update, and Director’s Update. FOR FURTHER INFORMATION CONTACT: • Improved efficacy in eliciting Place: National Institutes of Health, 35A Barry Buchbinder, Ph.D., 240–627– precursors for broadly neutralizing Convent Drive, Building 35A, 640, Bethesda, 3678; barry.buchbinder@nih.gov. MD 20892. CD4bs antibodies. Contact Person: Amy Williams, NCI Office Licensing information and copies of the • Facilitates the development of of Advocacy Relations, National Cancer U.S. patent application listed below VRC01-class bnAbs in humans. Institute, NIH, 31 Center Drive, Building 31, may be obtained by communicating Development Stage: In vivo testing Room 10A28, Bethesda, MD 20892, 240–781– with the indicated licensing contact at (rodents). 3360 williaam@mail.nih.gov. the Technology Transfer and Inventors: John R. Mascola (NIAID), Any interested person may file written Intellectual Property Office, National Hongying Duan (NIAID), Xuejun Chen comments with the committee by forwarding Institute of Allergy and Infectious (NIAID), Cheng Cheng (NIAID) and the statement to the Contact Person listed on Diseases, 5601 Fishers Lane, Rockville, Jeffrey C. Boyington (NIAID). this notice. The statement should include the MD 20852; tel. 301–496–2644. A signed Publications: Duan, H. et al., Glycan name, address, telephone number and when Confidential Disclosure Agreement will Masking Focuses Immune Responses to applicable, the business or professional be required to receive copies of the HIV-1 CD4-Binding Site and amozie on DSK3GDR082PROD with NOTICES1 affiliation of the interested person. Enhances Elicitation of VRC01-Class unpublished patent applications. In the interest of security, NIH has instituted stringent procedures for entrance SUPPLEMENTARY INFORMATION: Precursor Antibodies. Immunity 49, 301 onto the NIH campus. All visitor vehicles, Technology description follows. (2018). including taxicabs, hotel, and airport shuttles Intellectual Property: HHS Reference Glycan-Masked Engineered Outer Number E–083–2017 includes U.S. will be inspected before being allowed on campus. Visitors will be asked to show one Domains of HIV-1 GP120 and Their Use Provisional Patent Application Number form of identification (for example, a Description of Technology: 62/476,397 filed 03/24/2017 and PCT VerDate Sep<11>2014 18:01 Sep 19, 2018 Jkt 244001 PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 E:\FR\FM\20SEN1.SGM 20SEN1

47630 Federal Register / Vol. 83, No. 183 / Thursday, September 20, 2018 / Notices Application Number PCT/US2018/ 672, Bethesda, MD 20892, zhanggu@ DEPARTMENT OF HEALTH AND 024330 filed 03/26/2018. mail.nih.gov. HUMAN SERVICES Licensing Contact: Barry Buchbinder, (Catalogue of Federal Domestic Assistance Ph.D., 240–627–3678; Program Nos. 93.121, Oral Diseases and National Institutes of Health barry.buchbinder@nih.gov. Disorders Research, National Institutes of Health, HHS) Center for Scientific Review; Amended Dated: September 10, 2018. Notice of Meeting Dated: September 14, 2018. Suzanne M. Frisbie, Natasha M. Copeland, Notice is hereby given of a change in Deputy Director, Technology Transfer and Intellectual Property Office, National Institute Program Analyst, Office of Federal Advisory the meeting of the Molecular Genetics B of Allergy and Infectious Diseases. Committee Policy. Study Section, September 27, 2018, [FR Doc. 2018–20484 Filed 9–19–18; 8:45 am] [FR Doc. 2018–20424 Filed 9–19–18; 8:45 am] 10:00 a.m. to September 28, 2018, 06:00 BILLING CODE 4140–01–P BILLING CODE 4140–01–P p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD, 20892 which was published in the Federal DEPARTMENT OF HEALTH AND DEPARTMENT OF HEALTH AND Register on September 06, 2018, HUMAN SERVICES HUMAN SERVICES 83FR173 pg. 45264. National Institutes of Health The meeting will be held on National Institutes of Health September 27, 2018, starting at 8:30 a.m. National Institute of Allergy and The meeting location remains the same. National Institute of Dental & Infectious Diseases; Notice of Closed The meeting is closed to the public. Craniofacial Research; Notice of Closed Meetings Meeting Dated: September 14, 2018. Melanie J. Pantoja, Pursuant to section 10(d) of the Pursuant to section 10(d) of the Program Analyst, Office of Federal Advisory Federal Advisory Committee Act, as Federal Advisory Committee Act, as Committee Policy. amended, notice is hereby given of the amended, notice is hereby given of the [FR Doc. 2018–20415 Filed 9–19–18; 8:45 am] following meetings. following meeting. BILLING CODE 4140–01–P The meetings will be closed to the The meeting will be closed to the public in accordance with the public in accordance with the provisions set forth in section provisions set forth in sections DEPARTMENT OF HEALTH AND 552b(c)(6), Title 5 U.S.C., as amended. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., HUMAN SERVICES The grant applications and the as amended. The grant applications and discussions could disclose confidential the discussions could disclose National Institutes of Health trade secrets or commercial property confidential trade secrets or commercial such as patentable material, and Center for Scientific Review; Notice of property such as patentable material, personal information concerning Closed Meetings and personal information concerning individuals associated with the grant individuals associated with the grant applications, the disclosure of which Pursuant to section 10(d) of the applications, the disclosure of which Federal Advisory Committee Act, as would constitute a clearly unwarranted would constitute a clearly unwarranted invasion of personal privacy. amended, notice is hereby given of the invasion of personal privacy. following meetings. Name of Committee: National Institute of Name of Committee: National Institute of The meetings will be closed to the Dental and Craniofacial Research Special Allergy and Infectious Diseases Special Emphasis Panel; DPBRN ARC. public in accordance with the Emphasis Panel Centers of Excellence for provisions set forth in sections Date: November 14, 2018. Translational Research (CETR) (U19). Time: 8:00 a.m. to 5:00 p.m. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Date: October 11–12, 2018. Agenda: To review and evaluate grant as amended. The grant applications and Time: 8:00 a.m. to 6:00 p.m. applications. Agenda: To review and evaluate grant the discussions could disclose Place: Hilton Garden Inn, 7301 Waverly confidential trade secrets or commercial applications. Street, Bethesda, MD 20814. property such as patentable material, Place: Doubletree Hotel Bethesda, Contact Person: Guo He Zhang, MPH, and personal information concerning (Formerly Holiday Inn Select), 8120 Ph.D., Scientific Review Officer, Scientific individuals associated with the grant Wisconsin Avenue, Bethesda, MD 20814. Review Branch, National Institute of Dental and Craniofacial Research, National Institutes Contact Person: Yong Gao, Ph.D., Scientific applications, the disclosure of which Review Officer Scientific Review Program, would constitute a clearly unwarranted of Health, 6701 Democracy Boulevard, Suite Division of Extramural Activities, Room invasion of personal privacy. 672, Bethesda, MD 20892, zhanggu@ #3G13B, National Institutes of Health/NIAID, mail.nih.gov. Name of Committee: Brain Disorders and 5601 Fishers Lane, MSC 9823, Rockville, MD Name of Committee: National Institute of 20892–7616, (240) 669–5048, yong.gao@ Clinical Neuroscience Integrated Review Dental and Craniofacial Research Special nih.gov. Group; Clinical Neuroscience and Emphasis Panel; DPBRN Coordinating Neurodegeneration Study Section. Center. (Catalogue of Federal Domestic Assistance Date: October 3–4, 2018. Date: November 14, 2018. Program Nos. 93.855, Allergy, Immunology, Time: 8:00 a.m. to 5:00 p.m. Time: 10:00 a.m. to 5:00 p.m. and Transplantation Research; 93.856, Agenda: To review and evaluate grant Agenda: To review and evaluate grant Microbiology and Infectious Diseases applications. amozie on DSK3GDR082PROD with NOTICES1 applications. Research, National Institutes of Health, HHS) Place: National Institutes of Health, 6701 Place: Hilton Garden Inn Bethesda, 7301 Dated: September 14, 2018. Rockledge Drive, Bethesda, MD 20892. Waverly Street, Bethesda, MD 20814. Natasha M. Copeland, Contact Person: Alessandra C. Rovescalli, Contact Person: Guo He Zhang, MPH, Ph.D., Scientific Review Officer, National Program Analyst, Office of Federal Advisory Ph.D., Scientific Review Officer, Scientific Institutes of Health, Center for Scientific Committee Policy. Review Branch, National Institute of Dental Review, 6701 Rockledge Drive, Rm 5205 and Craniofacial Research, National Institutes [FR Doc. 2018–20421 Filed 9–19–18; 8:45 am] MSC7846, Bethesda, MD 20892, (301) 435– of Health, 6701 Democracy Boulevard, Suite BILLING CODE 4140–01–P 1021, rovescaa@mail.nih.gov. VerDate Sep<11>2014 18:01 Sep 19, 2018 Jkt 244001 PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 E:\FR\FM\20SEN1.SGM 20SEN1


Document Created: 2018-09-20 02:08:54
Document Modified: 2018-09-20 02:08:54
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactBarry Buchbinder, Ph.D., 240-627-3678; [email protected] Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation83 FR 47629 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR